Less than a third with an allergic reaction to the first dose of COVID vaccine have one after the second injection



[ad_1]

Less than a third of patients who have an allergic reaction to their first dose of COVID-19 vaccine have one after the second injection – and symptoms go away with over-the-counter drugs, study finds

  • Patients who have developed a severe allergic reaction to the first dose of the vaccine can safely return for a second dose, research shows
  • Over 80% of those who had a severe reaction to the vaccine returned for the second dose
  • Less than a third of these people had a reaction to the second dose, although their reaction was very minor and easily corrected.
  • Experts recommend completing the series of vaccines so that a person is fully vaccinated against COVID










It is safe for people who have had an allergic reaction to the first dose of a COVID-19 vaccine to receive the second dose, a new study suggests.

Researchers at Massachusetts General Hospital (MGH) looked at hospital data from people who reported first-time allergic reactions to Pfizer or Moderna.

They found that only a third of patients had an allergic reaction to the second dose after having one to the first, and the reactions were relatively minor.

The findings add to the growing knowledge about vaccines and their potential effects on people over time.

Receiving a second dose of the COVID-19 vaccine is also particularly important, as some research shows that a single dose of a vaccine may not be effective against the Indian ‘Delta’ variant.

Researchers have found that people who have developed an allergic reaction to the first dose of a COVID-19 vaccine can be safely given the second dose

Researchers have found that people who have developed an allergic reaction to the first dose of a COVID-19 vaccine can be safely given the second dose

For the study, published in JAMA Internal Medicine, the team looked at data from patients who visited an allergist after receiving their first dose for a potentially fatal whole-body allergic reaction.

About 2.5 in 10,000 people, or 0.025%, will experience this type of reaction as a result of the shooting.

“These reactions can include symptoms such as itching, hives or flushing. The patients included were all counseled by allergists after their reaction to dose one, ”said Dr. Matthew Krantz, co-lead author and researcher in allergic immunology at Vanderbilt University, in a statement.

Of 189 patients who were vaccinated between Jan.1 and March 31, a total of 159 – or 84 percent – still received the second dose of the vaccine.

Of this group, 32 patients (20%) reported allergic symptoms at the second dose.

However, the reactions were relatively minor and resolved with antihistamines.

“An important point of this study is that these immediate reactions to the mRNA vaccine may not be mechanically caused by a classic allergy, called immediate hypersensitivity or Ig-E mediated hypersensitivity,” said Dr. Kimberly Blumentha, co-author. and director of clinical epidemiology. Program within the Division of Rheumatology, Allergy and Immunology at the MGH.

“For classic allergy, re-exposure to the allergen causes the same or even worse symptoms.”

Of the group that had reactions, 130 (69%) received the Moderna injections and 31% received the Pfizer-BioNTech vaccine.

The most common reactions to the first dose recorded were erythema (28 percent of people) – where a person develops a rash – dizziness (26 percent), tingling (24 percent), a feeling of tightness in the throat (22 percent) and hives (21 percent).

Researchers recommend that people who have had an allergic reaction continue to receive the second dose, but see their allergy specialist first.

Experts recommend that everyone complete their series of vaccines – two doses for the Pfizer-BioNTech and Moderna vaccines and one for the Johnson & Johnson vaccine – whenever possible.

Completing a series of vaccines produces more antibodies for a person and offers greater effectiveness in preventing complications from the virus.

Some research shows that receiving just one dose of a vaccine will even leave a person vulnerable to the Delta variant, a highly contagious viral variant that is sweeping across the country.

The variant accounts for about 70 percent of active cases in the United States.

Currently, about 56% of Americans have received a dose of a COVID-19 vaccine, and just under 50% are fully immunized.

Any American age 12 or older is eligible to receive a COVID-19 vaccine.

[ad_2]

Source link